menu search

INZY / Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade

Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read More
Posted: Oct 10 2023, 13:33
Author Name: Zacks Investment Research
Views: 112278

INZY News  

Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade

By Zacks Investment Research
October 10, 2023

Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade

Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might more_horizontal

3 Penny Stocks To Buy According To Insiders In August 2023

By PennyStocks
August 4, 2023

3 Penny Stocks To Buy According To Insiders In August 2023

Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy specul more_horizontal

Inozyme Pharma to Present at the Jefferies Healthcare Conference

By GlobeNewsWire
June 2, 2023

Inozyme Pharma to Present at the Jefferies Healthcare Conference

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing nove more_horizontal

Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data

By Seeking Alpha
February 21, 2023

Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data

Shares are down 58% over the past year. Enzyme replacement therapy is an attractive area of drug development with less risk than more exotic modalitie more_horizontal

Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial

By Benzinga
July 20, 2022

Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial

Inozyme Pharma Inc (NASDAQ: INZY) has announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects in the P more_horizontal

Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders

By Benzinga
April 12, 2022

Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders

Inozyme Pharma Inc (NASDAQ: INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the more_horizontal

Why Inozyme Pharma Shares Are Jumping Today

By Benzinga
April 4, 2022

Why Inozyme Pharma Shares Are Jumping Today

Inozyme Pharma Inc (NASDAQ: INZY) announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in t more_horizontal


Search within

Pages Search Results: